Shilpa Medicare Ltd

Shilpa Medicare Reports Strong Q3 Growth 📈 | Revenue Up 28% YoY, PAT Surges 72%

• Q3 FY26 revenue: ₹411 crores, up 28% YoY

• 9-month revenue: ₹1,110 crores, up 14% YoY

• Q3 EBITDA: ₹115 crores, up 40% YoY with margins at 28%

• 9-month EBITDA: ₹323 crores, up 26% YoY

• Q3 PAT: ₹55 crores, up 72% YoY

• 9-month PAT: ₹146 crores, up 128% YoY

• Formulations business grew 50% YoY in Q3

• API segment revenue increased 11% YoY

• EU revenue doubled in Q3

• Launched NorUDCA, a first-in-class treatment for NAFLD in India

• Secured partnerships with three large pharma firms

• Biologics segment showed progress in biosimilars like Adalimumab and Aflibercept

• CDMO business expanded with new product validations and partnerships

• Improved capital efficiency with rising ROCE and reduced net debt to EBITDA